RNA (Atrium Therapeutics) Marketable Securities: $0.00 Mil (As of Mar. 2026)


RNA Atrium Therapeutics Inc RNA
12 GF Score
Price $13.65
! 1 Warning Sign
View Full Analysis

What is Atrium Therapeutics Marketable Securities?

Atrium Therapeutics RNA +2.61% 12 Marketable Securities is $0.00 Mil as of Mar. 2026. GuruFocus rates RNA with a GF Score™ of 12/100. The stock has 1 warning sign investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Atrium Therapeutics's Marketable Securities for the quarter that ended in Mar. 2026 was $0.00 Mil.

Atrium Therapeutics  (NAS:RNA) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Atrium Therapeutics Marketable Securities Related Terms

Atrium Therapeutics Marketable Securities Historical Data

* Premium members only.

The historical data trend for Atrium Therapeutics's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Atrium Therapeutics Marketable Securities Chart

Atrium Therapeutics Annual Data
Trend Dec23 Dec24 Dec25
Marketable Securities
0.00 0.00 0.00

Atrium Therapeutics Quarterly Data
Dec23 Dec24 Mar25 Sep25 Dec25 Mar26
Marketable Securities Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00
RNA
12GF Score
Atrium Therapeutics Inc RNA
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Atrium Therapeutics Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of $0.00 Mil mean?
Atrium Therapeutics (RNA) has a Marketable Securities of $0.00 Mil as of Mar. 2026. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Atrium Therapeutics and its competitors.
Is Atrium Therapeutics' Marketable Securities too high?
Atrium Therapeutics' current Marketable Securities is $0.00 Mil. Overall, Atrium Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Atrium Therapeutics' Marketable Securities compare to CNTN and QTTB?
Atrium Therapeutics' Marketable Securities of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Biotechnology company?
A good Marketable Securities depends on the Biotechnology industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Atrium Therapeutics and its competitors. Atrium Therapeutics's current Marketable Securities is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Atrium Therapeutics stock overvalued right now?
Atrium Therapeutics (RNA) has a current Marketable Securities of $0.00 Mil. The current Marketable Securities is $0.00 Mil. Atrium Therapeutics' overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Atrium Therapeutics (RNA), the current Marketable Securities is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Atrium Therapeutics Business Description

Address 10578 Science Center Drive, Suite 125, San Diego, CA, USA, 92121
Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.
12GF Score

Get the complete analysis for RNA

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$13.65
Price